CN114786712A - 用于治疗高胱氨酸尿症的酶疗法的PEG化胱硫醚β合成酶 - Google Patents

用于治疗高胱氨酸尿症的酶疗法的PEG化胱硫醚β合成酶 Download PDF

Info

Publication number
CN114786712A
CN114786712A CN202080060487.6A CN202080060487A CN114786712A CN 114786712 A CN114786712 A CN 114786712A CN 202080060487 A CN202080060487 A CN 202080060487A CN 114786712 A CN114786712 A CN 114786712A
Authority
CN
China
Prior art keywords
hcy
patients
see
levels
entirety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080060487.6A
Other languages
English (en)
Chinese (zh)
Inventor
E·布布利尔
F·格拉文
M·塞洛斯-莫拉
T·马伊坦
J·P·克劳斯
R·万纳
O·考斯维克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Travier Therapy Switzerland Ltd
University of Colorado Denver
Original Assignee
Travier Therapy Switzerland Ltd
University of Colorado Denver
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Travier Therapy Switzerland Ltd, University of Colorado Denver filed Critical Travier Therapy Switzerland Ltd
Publication of CN114786712A publication Critical patent/CN114786712A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080060487.6A 2019-06-26 2020-06-26 用于治疗高胱氨酸尿症的酶疗法的PEG化胱硫醚β合成酶 Pending CN114786712A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962866810P 2019-06-26 2019-06-26
US62/866,810 2019-06-26
US202062983860P 2020-03-02 2020-03-02
US62/983,860 2020-03-02
PCT/US2020/039870 WO2020264333A1 (en) 2019-06-26 2020-06-26 Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria

Publications (1)

Publication Number Publication Date
CN114786712A true CN114786712A (zh) 2022-07-22

Family

ID=71670437

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080060487.6A Pending CN114786712A (zh) 2019-06-26 2020-06-26 用于治疗高胱氨酸尿症的酶疗法的PEG化胱硫醚β合成酶

Country Status (24)

Country Link
US (1) US12364765B2 (cg-RX-API-DMAC10.html)
EP (2) EP3990005B1 (cg-RX-API-DMAC10.html)
JP (2) JP2022539077A (cg-RX-API-DMAC10.html)
KR (1) KR20220044726A (cg-RX-API-DMAC10.html)
CN (1) CN114786712A (cg-RX-API-DMAC10.html)
AU (1) AU2020302079A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021026292A2 (cg-RX-API-DMAC10.html)
CA (1) CA3145426A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021003474A1 (cg-RX-API-DMAC10.html)
DK (1) DK3990005T3 (cg-RX-API-DMAC10.html)
ES (1) ES3058596T3 (cg-RX-API-DMAC10.html)
FI (1) FI3990005T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20251579T1 (cg-RX-API-DMAC10.html)
IL (1) IL289245B2 (cg-RX-API-DMAC10.html)
LT (1) LT3990005T (cg-RX-API-DMAC10.html)
MX (2) MX2021015966A (cg-RX-API-DMAC10.html)
PH (1) PH12021553235A1 (cg-RX-API-DMAC10.html)
PL (1) PL3990005T3 (cg-RX-API-DMAC10.html)
PT (1) PT3990005T (cg-RX-API-DMAC10.html)
RS (1) RS67521B1 (cg-RX-API-DMAC10.html)
SA (1) SA521431197B1 (cg-RX-API-DMAC10.html)
SI (1) SI3990005T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202600042T1 (cg-RX-API-DMAC10.html)
WO (1) WO2020264333A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116920125A (zh) * 2022-10-13 2023-10-24 呈诺再生医学科技(北京)有限公司 Cbs基因在制备糖尿病视网膜病变治疗药物中的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
DK3998067T3 (da) 2015-11-09 2024-10-28 Univ Colorado Regents Sammensætninger og fremgangsmåder til behandling af homocystinuri
CA3059592A1 (en) 2017-04-17 2018-10-25 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
MX2021015966A (es) 2019-06-26 2022-04-06 Travere Therapeutics Switzerland Gmbh Producto farmacológico para terapia enzimática para el tratamiento de la homocistinuria.
EP4025243A4 (en) * 2019-09-03 2023-09-27 Travere Therapeutics Switzerland GmbH CYSTATHIONINE BETA-SYNTHASE ENZYMA THERAPY FOR THE TREATMENT OF HIGH HOMOCYSTEINE LEVELS
CN115671059B (zh) * 2022-11-17 2024-06-11 兆科药业（合肥）有限公司 一种盐酸氨酮戊酸冻干制剂及制备方法
CN120610012A (zh) * 2023-10-20 2025-09-09 T&D诊断加拿大私人有限公司 用于诊断个体整体健康状况的标志物以及装置

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102741288A (zh) * 2009-08-29 2012-10-17 雅培制药有限公司 治疗用dll4结合蛋白
EP2510100A1 (en) * 2009-12-09 2012-10-17 Curevac GmbH Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
CN104540940A (zh) * 2012-03-26 2015-04-22 科罗拉多州大学评议会 胱硫醚β-合酶的纯化
CN105452457A (zh) * 2013-01-29 2016-03-30 科罗拉多州大学评议会 用于治疗高胱氨酸尿症的胱硫醚β-合酶
WO2017083327A1 (en) * 2015-11-09 2017-05-18 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656425A (en) 1993-08-17 1997-08-12 Regents Of The University Of Colorado Screening for mutations by expressing cDNA segments
US5523225A (en) 1993-09-13 1996-06-04 Regents Of The University Of Colorado DNA sequence encoding human cystathionine β-synthase
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
WO2003106971A2 (en) 2002-06-17 2003-12-24 The Regents Of The University Of Colorado HUMAN CYSTATHIONINE β-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF
EP1396537A1 (en) 2002-09-04 2004-03-10 Avidis SA Treatment of elevated plasma homocysteine
CA2534995A1 (en) 2003-07-31 2005-05-19 Anticancer, Inc. The use of plp with peg-rmetase in vivo for enhanced efficacy
US20070010492A1 (en) 2005-07-11 2007-01-11 Generale Robert J Composition and method for reducing homocysteine caused by drugs containing methyl compounds
BR112013000027A2 (pt) 2010-07-01 2017-07-11 Isis Innovation tratamento de distúrbios cognitivos
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
WO2015033279A1 (en) 2013-09-04 2015-03-12 Mahesh Kandula Compositions and methods for the treatment of homocystinuria
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
CN106456744A (zh) 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
WO2016183482A1 (en) 2015-05-13 2016-11-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
MX2019000205A (es) 2016-07-07 2019-09-23 Rubius Therapeutics Inc Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
CA3059592A1 (en) 2017-04-17 2018-10-25 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
MX2021015966A (es) 2019-06-26 2022-04-06 Travere Therapeutics Switzerland Gmbh Producto farmacológico para terapia enzimática para el tratamiento de la homocistinuria.
EP4025243A4 (en) * 2019-09-03 2023-09-27 Travere Therapeutics Switzerland GmbH CYSTATHIONINE BETA-SYNTHASE ENZYMA THERAPY FOR THE TREATMENT OF HIGH HOMOCYSTEINE LEVELS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102741288A (zh) * 2009-08-29 2012-10-17 雅培制药有限公司 治疗用dll4结合蛋白
EP2510100A1 (en) * 2009-12-09 2012-10-17 Curevac GmbH Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
CN104540940A (zh) * 2012-03-26 2015-04-22 科罗拉多州大学评议会 胱硫醚β-合酶的纯化
CN105452457A (zh) * 2013-01-29 2016-03-30 科罗拉多州大学评议会 用于治疗高胱氨酸尿症的胱硫醚β-合酶
WO2017083327A1 (en) * 2015-11-09 2017-05-18 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOMAS MAJTAN ET AL.: ""Engineering and Characterization of an Enzyme Replacement Therapy for Classical Homocystinuria"", 《BIOMACROMOLECULES》, vol. 18, 21 April 2017 (2017-04-21), pages 1747 - 1761 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116920125A (zh) * 2022-10-13 2023-10-24 呈诺再生医学科技(北京)有限公司 Cbs基因在制备糖尿病视网膜病变治疗药物中的应用

Also Published As

Publication number Publication date
US12364765B2 (en) 2025-07-22
EP3990005B1 (en) 2025-08-27
MX2026001319A (es) 2026-03-02
ES3058596T3 (en) 2026-03-11
EP3990005A1 (en) 2022-05-04
BR112021026292A2 (pt) 2022-05-31
US20220265835A1 (en) 2022-08-25
JP2025143275A (ja) 2025-10-01
HRP20251579T1 (hr) 2026-01-30
FI3990005T3 (fi) 2025-11-28
KR20220044726A (ko) 2022-04-11
CA3145426A1 (en) 2020-12-30
PL3990005T4 (pl) 2026-03-02
SI3990005T1 (sl) 2026-02-27
SMT202600042T1 (it) 2026-03-09
WO2020264333A1 (en) 2020-12-30
DK3990005T3 (da) 2025-12-08
SA521431197B1 (ar) 2024-12-03
IL289245A (en) 2022-02-01
PL3990005T3 (pl) 2026-03-02
MX2021015966A (es) 2022-04-06
LT3990005T (lt) 2026-01-12
PH12021553235A1 (en) 2022-08-22
EP4663239A2 (en) 2025-12-17
AU2020302079A1 (en) 2022-02-17
IL289245B2 (en) 2025-09-01
PT3990005T (pt) 2025-12-17
IL289245B1 (en) 2025-05-01
CL2021003474A1 (es) 2022-09-02
EP4663239A3 (en) 2026-03-11
RS67521B1 (sr) 2026-01-30
JP2022539077A (ja) 2022-09-07

Similar Documents

Publication Publication Date Title
EP3990005B1 (en) Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria
JP5732603B2 (ja) 骨標的アルカリホスファターゼ、キット及びその使用方法
JP2025016455A (ja) 組換えヒト酸性アルファグリコシダーゼ
US20220290116A1 (en) Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels
WO2017173413A1 (en) Treating muscle weakness with alkaline phosphatases
JP2022050589A (ja) ホモシスチン尿症の治療する組成物および方法
KR20230145120A (ko) 알칼리성 포스파타제 폴리펩타이드 및 이의 사용 방법
RU2839909C2 (ru) Пэгилированная цистатионин-бета-синтаза для ферментотерапии для лечения гомоцистинурии
HK40071277B (en) Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria
HK40071277A (en) Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria
RU2833879C1 (ru) Терапия с использованием фермента цистатионин-бета-синтазы для лечения заболеваний, вызываемых повышенными уровнями гомоцистеина
JP2026516225A (ja) アルカリホスファターゼによる筋力低下の処置
HK40032702A (en) Recombinant human acid alpha-glucosidase
EA045409B1 (ru) Рекомбинантная человеческая кислая альфа-глюкозидаза
BR122024026309A2 (pt) Alfa-glicosidase ácida humana recombinante

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination